- ►diabetesjournals.org JF List, V Woo, E Morales, W Tang, FT … - Diabetes Care, 2009 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS Type 2 diabetic patients were randomly assigned to
one of five dapagliflozin doses, metformin XR, or placebo for 12 weeks. The
primary objective was to compare mean change from baseline in A1C. Other ... Cited by 13 - Related articles - All 3 versions
B Komoroski, N Vachharajani, Y Feng, L Li, D … - Clinical Pharmacology & Therapeutics, 2009 - nature.com Dapagliflozin, administered to patients in once-daily oral doses, is a
sodium–glucose cotransporter 2 (SGLT2) inhibitor that blocks the reabsorption
of glucose from urine into the blood. This 14-day study randomized patients ... Cited by 11 - Related articles - All 4 versions
MA Abdul-Ghani, RA DeFronzo - Endocrine Practice, 2008 - AACE The prevalence of type 2 diabetes mellitus (T2DM) has increased progressively to
epidemic proportions dur- ing the past 20 years (1). Patients with T2DM have
increased morbidity and mortality, the majority of which results from ... Cited by 5 - Related articles - All 2 versions
B Komoroski, N Vachharajani, D Boulton, D … - Clinical Pharmacology & Therapeutics, 2009 - nature.com Dapagliflozin selectively inhibits renal glucose reabsorption by inhibiting
sodium–glucose cotransporter-2 (SGLT2). It was developed as an
insulin-independent treatment approach for type 2 diabetes mellitus (T2DM). ... Cited by 6 - Related articles - All 4 versions
SA Jabbour, BJ Goldstein - International Journal of Clinical Practice, 2008 - interscience.wiley.com Background: The kidney plays a central role in the regulation of plasma glucose
levels, although until recently this has not been widely appreciated or
considered a target for therapeutic intervention. The sodium glucose co- ... Cited by 13 - Related articles - All 3 versions
[CITATION] Tissue expression profiling of the sodium-glucose co-transporter (SGLT) family: implication …
M Kipnes - Expert Opinion on Investigational Drugs, 2009 - informahealthcare.com The global incidence of type 2 diabetes mellitus is increasing. Hyperglycemia
contributes to both the complications associated with diabetes mellitus and
progression of the underlying disease. New agents that lower blood glucose ... Cited by 1 - Related articles - All 6 versions
- ►diabetesjournals.org S Han, DL Hagan, JR Taylor, L Xin, W Meng, … - Diabetes, 2008 - Am Diabetes Assoc RESULTS—Dapagliflozin potently and selectively inhibited human SGLT2 versus
human SGLT1, the major cotransporter of glucose in the gut, and did not
significantly inhibit facilitative glucose transport in human adipocytes. ... Cited by 26 - Related articles - All 5 versions
[CITATION] Simulation and prediction of long-term clinical efficacy in type 2 diabetes resulting from …
R O'Connor-Semmes, EK Hussey, RL … - American Diabetes Association 68th Annual Scientific …, 2008 Cited by 2 - Related articles
M Bickel, H Brummerhop, W Frick, H Glombik, … - Arzneimittel-Forschung, 2008 - ncbi.nlm.nih.gov AVE2268, a substituted glycopyranoside, is an orally active and selective
inhibitor of sodium-dependent glucose transporter 2 (SGLT2; IC50 = 13 nmol/L).
Investigation of the pharmacological profile of AVE2268 on urinary glucose ... Cited by 4 - Related articles - All 3 versions
